Yıl: 2022 Cilt: 52 Sayı: 4 Sayfa Aralığı: 1075 - 1084 Metin Dili: İngilizce DOI: 10.55730/1300-0144.5410 İndeks Tarihi: 14-12-2022

Could lysosomal acid lipase enzyme activity be used for clinical follow-up in cryptogenic cirrhosis?

Öz:
Background/aim: Cholesterol ester storage disease (CESD) is one of the rare causes that should be kept in mind in the etiology of cirrhosis. Recent studies detected that significantly reduced lysosomal acid lipase deficiency enzyme (LAL) in patients with cryptogenic cirrhosis (CC). Moreover, studies have evaluated that LAL activity is as effective as scoring systems in assessing the severity of cirrhosis. In this study, we aimed to investigate the CESD with LAL level and mutation analysis of LIPA gene in patients diagnosed with CC and to compare LAL activities between patients with CC and healthy volunteers. Materials and methods: Laboratory parameters and cirrhosis stage (CHILD and MELD) were recorded for the patient group included in the study. In addition, blood samples were taken from each case included in the study for LAL activity determination and LIPA gene analysis. Results: A statistically significant decrease in LAL activity was found in patients diagnosed with CC compared to the healthy group. LIPA gene analysis did not detect CESD in any patient group. Correlation analysis showed a positive correlation between LAL activity and white blood cell and platelet counts in both healthy volunteers and CC patient groups. In the univariate and multivariate logistic regression analysis of the parameters associated with the MELD of ≥10 in patients with CC, significant relationship was found between the MELD of ≥10 and the LAL activity. Conclusions: In our study, LAL activity was significantly lower in CC patients than in the normal population. LAL activity level appears to be a parameter that can be used to assess the severity of cirrhosis.
Anahtar Kelime: Cholesterol ester storage disease cryptogenic cirrhosis lysosomal acid lipase deficiency LIPA gene

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Tovoli F, Napoli L, Negrini G, D’Addato S, Tozzi G et al. A Relative Deficiency of Lysosomal Acid Lypase Activity Characterizes Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences 2017; 18 (6): 1134. doi: 10.3390/ ijms18061134
  • 2. Selvakumar PK, Kabbany MN, Lopez R, Tozzi G, Alisi A et al. Reduced lysosomal acid lipase activity - A potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients. Digestive and Liver Disease 2016; 48 (8): 909-913. doi: 10.1016/j.dld.2016.04.014
  • 3. Pant M, Oshima K. Cholesteryl Ester Storage Disease: An underdiagnosed cause of cirrhosis in adults. Annals of Diagnostic Pathology 2017; 31: 66-70. doi: 10.1016/j. anndiagpath.2017.02.005
  • 4. Reynolds T. Cholesteryl ester storage disease: a rare and possibly treatable cause of premature vascular disease and cirrhosis. Journal Of Clinical Pathology 2013; 66 (11): 918-923. doi: 10.1136/jclinpath-2012-201302
  • 5. Kuloglu Z, Kansu A, Selbuz S, Kalaycı AG, Şahin G et al.; National LAL-D Study Group. The Frequency of Lysosomal Acid Lipase Deficiency in Children With Unexplained Liver Disease. Journal of Pediatric Gastroenterology and Nutrition 2019; 68 (3): 371-376. doi: 10.1097/MPG.0000000000002224
  • 6. Vespasiani-Gentilucci U, Gallo P, Piemonte F, Riva E, Porcari A et al. Lysosomal Acid Lipase Activity Is Reduced Both in Cryptogenic Cirrhosis and in Cirrhosis of Known Etiology. PLoS One 2016; 11 (5): e0156113. doi: 10.1371/journal. pone.0156113
  • 7. Baratta F, Pastori D, Tozzi G, D’Erasmo L, Di Costanzo A et al. Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of non-alcoholic fatty liver disease. Liver International 2019; 39 (12): 2301-2308. doi: 10.1111/liv.14206
  • 8. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29 (3): 664-669. doi: 10.1002/hep.510290347
  • 9. Dairaku T, Iwamoto T, Nishimura M, Endo M, Ohashi T et al. A practical fluorometric assay method to measure lysosomal acid lipase activity in dried blood spots for the screening of cholesteryl ester storage disease and Wolman disease. Molecular Genetics and Metabolism 2014; 111 (2): 193-196. doi: 10.1016/j.ymgme.2013.11.003
  • 10. Ceci R, Francesco P, Mucci J, Cancelarich L, Fossati C et al. Reliability of enzyme assays in dried blood spots for diagnosis of 4 lysosomal storage disorders. Advances in Biological Chemistry 2011; 1: 58–64. doi: 10.4236/abc.2011.13008
  • 11. Angelico F, Corradini SG, Pastori D, Fargion S, Fracanzani AL et al; LAL-Cirrhosis Collaborative Research Group. Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. Atherosclerosis 2017; 262: 179-184. doi: 10.1016/j. atherosclerosis.2017.03.038
  • 12. Papatheodoridis GV, Cholongitas E, Dimitriadou E, Touloumi G, Sevastianos V et al. MELD vs Child-Pugh and creatinine- modified Child-Pugh score for predicting survival in patients with decompensated cirrhosis. World Journal of Gastroenterology 2005; 11 (20): 3099-3104. doi: 10.3748/wjg. v11.i20.3099
  • 13. Shteyer E, Villenchik R, Mahamid M, Nator N, Safadi R. Low Serum Lysosomal Acid Lipase Activity Correlates with Advanced International Journal of Molecular Sciences 2016; 17 (3): 312. doi: 10.3390/ijms17030312
  • 14. Gravito-Soares M, Gravito-Soares E, Gomes D, Tome L. Lysosomal Acid Lipase: Can it be a New Non-Invasive Serum Biomarker of Cryptogenic Liver Fibrosis and Cirrhosis? Annals of Hepatology 2019; 18 (1): 78-88. doi: 10.5604/01.3001.0012.7865
APA Kose E, çağatay e, yaraş T, TEKE KISA P, Guler S, Arslan Gulten Z, akarsu m, Oktay Y, Ayar Kayali H, arslan n (2022). Could lysosomal acid lipase enzyme activity be used for clinical follow-up in cryptogenic cirrhosis?. , 1075 - 1084. 10.55730/1300-0144.5410
Chicago Kose Engin,çağatay elçin,yaraş Tutku,TEKE KISA PELIN,Guler Seminay,Arslan Gulten Zumrut,akarsu mesut,Oktay Yavuz,Ayar Kayali Hulya,arslan nur Could lysosomal acid lipase enzyme activity be used for clinical follow-up in cryptogenic cirrhosis?. (2022): 1075 - 1084. 10.55730/1300-0144.5410
MLA Kose Engin,çağatay elçin,yaraş Tutku,TEKE KISA PELIN,Guler Seminay,Arslan Gulten Zumrut,akarsu mesut,Oktay Yavuz,Ayar Kayali Hulya,arslan nur Could lysosomal acid lipase enzyme activity be used for clinical follow-up in cryptogenic cirrhosis?. , 2022, ss.1075 - 1084. 10.55730/1300-0144.5410
AMA Kose E,çağatay e,yaraş T,TEKE KISA P,Guler S,Arslan Gulten Z,akarsu m,Oktay Y,Ayar Kayali H,arslan n Could lysosomal acid lipase enzyme activity be used for clinical follow-up in cryptogenic cirrhosis?. . 2022; 1075 - 1084. 10.55730/1300-0144.5410
Vancouver Kose E,çağatay e,yaraş T,TEKE KISA P,Guler S,Arslan Gulten Z,akarsu m,Oktay Y,Ayar Kayali H,arslan n Could lysosomal acid lipase enzyme activity be used for clinical follow-up in cryptogenic cirrhosis?. . 2022; 1075 - 1084. 10.55730/1300-0144.5410
IEEE Kose E,çağatay e,yaraş T,TEKE KISA P,Guler S,Arslan Gulten Z,akarsu m,Oktay Y,Ayar Kayali H,arslan n "Could lysosomal acid lipase enzyme activity be used for clinical follow-up in cryptogenic cirrhosis?." , ss.1075 - 1084, 2022. 10.55730/1300-0144.5410
ISNAD Kose, Engin vd. "Could lysosomal acid lipase enzyme activity be used for clinical follow-up in cryptogenic cirrhosis?". (2022), 1075-1084. https://doi.org/10.55730/1300-0144.5410
APA Kose E, çağatay e, yaraş T, TEKE KISA P, Guler S, Arslan Gulten Z, akarsu m, Oktay Y, Ayar Kayali H, arslan n (2022). Could lysosomal acid lipase enzyme activity be used for clinical follow-up in cryptogenic cirrhosis?. Turkish Journal of Medical Sciences, 52(4), 1075 - 1084. 10.55730/1300-0144.5410
Chicago Kose Engin,çağatay elçin,yaraş Tutku,TEKE KISA PELIN,Guler Seminay,Arslan Gulten Zumrut,akarsu mesut,Oktay Yavuz,Ayar Kayali Hulya,arslan nur Could lysosomal acid lipase enzyme activity be used for clinical follow-up in cryptogenic cirrhosis?. Turkish Journal of Medical Sciences 52, no.4 (2022): 1075 - 1084. 10.55730/1300-0144.5410
MLA Kose Engin,çağatay elçin,yaraş Tutku,TEKE KISA PELIN,Guler Seminay,Arslan Gulten Zumrut,akarsu mesut,Oktay Yavuz,Ayar Kayali Hulya,arslan nur Could lysosomal acid lipase enzyme activity be used for clinical follow-up in cryptogenic cirrhosis?. Turkish Journal of Medical Sciences, vol.52, no.4, 2022, ss.1075 - 1084. 10.55730/1300-0144.5410
AMA Kose E,çağatay e,yaraş T,TEKE KISA P,Guler S,Arslan Gulten Z,akarsu m,Oktay Y,Ayar Kayali H,arslan n Could lysosomal acid lipase enzyme activity be used for clinical follow-up in cryptogenic cirrhosis?. Turkish Journal of Medical Sciences. 2022; 52(4): 1075 - 1084. 10.55730/1300-0144.5410
Vancouver Kose E,çağatay e,yaraş T,TEKE KISA P,Guler S,Arslan Gulten Z,akarsu m,Oktay Y,Ayar Kayali H,arslan n Could lysosomal acid lipase enzyme activity be used for clinical follow-up in cryptogenic cirrhosis?. Turkish Journal of Medical Sciences. 2022; 52(4): 1075 - 1084. 10.55730/1300-0144.5410
IEEE Kose E,çağatay e,yaraş T,TEKE KISA P,Guler S,Arslan Gulten Z,akarsu m,Oktay Y,Ayar Kayali H,arslan n "Could lysosomal acid lipase enzyme activity be used for clinical follow-up in cryptogenic cirrhosis?." Turkish Journal of Medical Sciences, 52, ss.1075 - 1084, 2022. 10.55730/1300-0144.5410
ISNAD Kose, Engin vd. "Could lysosomal acid lipase enzyme activity be used for clinical follow-up in cryptogenic cirrhosis?". Turkish Journal of Medical Sciences 52/4 (2022), 1075-1084. https://doi.org/10.55730/1300-0144.5410